ObsEva (NASDAQ:OBSV) Price Target Raised to $5.00 at SVB Leerink

ObsEva (NASDAQ:OBSV) had its price target raised by investment analysts at SVB Leerink from $4.00 to $5.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s price target indicates a potential upside of 136.97% from the stock’s current price.

OBSV has been the topic of a number of other reports. HC Wainwright decreased their price target on ObsEva from $23.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, January 4th. JPMorgan Chase & Co. cut ObsEva from a “neutral” rating to an “underweight” rating in a research note on Monday, November 9th. Finally, Zacks Investment Research upgraded ObsEva from a “sell” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. ObsEva presently has an average rating of “Hold” and an average target price of $10.21.

OBSV opened at $2.11 on Tuesday. ObsEva has a one year low of $1.63 and a one year high of $6.30. The stock has a market capitalization of $101.28 million, a PE ratio of -0.85 and a beta of 1.00. The business’s 50 day moving average price is $2.10 and its 200 day moving average price is $2.55. The company has a debt-to-equity ratio of 1.14, a quick ratio of 2.06 and a current ratio of 2.06.

ObsEva (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15). As a group, equities research analysts forecast that ObsEva will post -1.79 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of OBSV. Morgan Stanley increased its position in shares of ObsEva by 1,023.1% during the third quarter. Morgan Stanley now owns 477,467 shares of the company’s stock worth $1,184,000 after acquiring an additional 434,953 shares during the period. Acadian Asset Management LLC purchased a new position in ObsEva in the third quarter valued at $414,000. California Public Employees Retirement System purchased a new position in ObsEva in the second quarter valued at $401,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ObsEva by 32.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 255,995 shares of the company’s stock valued at $635,000 after buying an additional 62,192 shares during the last quarter. Finally, State Street Corp purchased a new position in ObsEva in the third quarter valued at $124,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

ObsEva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

See Also: What are high-yield dividend stocks?

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.